Tel-Aviv, Israel, (December 20th, 2018) – VALFIX Medical Ltd. is pleased to announce that it has received a grant from the Israel Innovation Authority (IIA). VALFIX Medical is developing trans-catheter solutions for patients suffering from valvular heart disease and heart failure.
This is the second consecutive year that VALFIX Medical is receiving an R&D grant from the Israel Innovation Authority (IIA). These funds will continue to support the completion of the VALFIX system development.
Eli Bar, CEO and Founder of VALFIX Medical commented on the news. "Receiving this grant for the second consecutive year is one more confirmation that we are creating an innovative device and procedure, addressing a large unmet need. This grant allows us to continue building our technology and maintain the momentum that we have already achieved."
The IIA awards grants through a competitive application and review process. Approval requires due diligence and an extensive review of the company's achievements, assets and plans.
About VALFIX Medical:
VALFIX Medical is developing the first complete trans-catheter solution which, based on its multi-wire technology, combines repair and replacement treatments for the Mitral and the Tricuspid valves; offering a viable alternative to open heart surgery.
Devra Igra +972 73 374 4805 email@example.com